BNP Paribas Financial Markets’s Faeth Therapeutics FTH Stock Holding History

BNP Paribas Financial Markets’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.83K	Buy	113 +104	+1,156%	+$2.4K	﹤0.01%	5513
2026 Q1	$284	Hold	9	–	–	﹤0.01%	5601
2025 Q4	$96	Hold	9	–	–	﹤0.01%	5614
2025 Q3	$85	Hold	9	–	–	﹤0.01%	5444
2025 Q2	$77	Buy	9 +1	+13%	+$7	﹤0.01%	5337
2025 Q1	$63	Hold	8	–	–	﹤0.01%	5282
2024 Q4	$78	Buy	+8	New	+$80	﹤0.01%	5295
2022 Q4	–	Sell	-30	Closed	-$935	–	4551
2022 Q3	$935	Buy	+30	New	+$1.18K	﹤0.01%	4437

Other funds holding FTH

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

BNP Paribas Financial Markets's FTH Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Faeth Therapeutics (FTH) stake by 1,156% in Q2 2026, buying an estimated $2.4K and bringing the position to 113 shares worth $2.83K. The position accounts for ﹤0.01% of the portfolio, ranked #5513.

BNP Paribas Financial Markets first reported a position in FTH in Q3 2022 and has held it in 8 quarters since. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

BNP Paribas Financial Markets held 113 shares of Faeth Therapeutics worth $2.83K as of Q2 2026.
BNP Paribas Financial Markets bought 104 Faeth Therapeutics shares in Q2 2026, an estimated $2.4K.
Faeth Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5513 holding.
BNP Paribas Financial Markets first reported a position in Faeth Therapeutics in Q3 2022 and has held it in 8 quarters since.
45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.